Blackstone Life Sciences and Anthos Therapeutics Reach Deal for Novartis to Acquire Anthos for up to $3.1 Billion Blackstone Life Sciences and Anthos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transformative therapies for cardiometabolic diseases, have announced a significant…
LIB Therapeutics Announces FDA Acceptance of Lerodalcibep BLA for LDL-C Reduction LIB Therapeutics Inc., a late-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for Lerodalcibep. This…
Arrowhead Pharmaceuticals Closes Global License and Collaboration with Sarepta Therapeutics Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the successful closing of its global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT). The agreement, initially announced on November 26, 2024,…
Pan-Am Dental Completes Two Acquisitions, Joins Top 10 U.S. Dental Lab Groups Caymus Equity Partners (“Caymus Equity”) is excited to announce the successful acquisitions of JB Dental Lab (“JB”) and Avaneer Dental Studio (“Avaneer”) by its portfolio company, Pan-Am Dental…
Fresenius Kabi Launches Synthetic Calcitonin Salmon Injection, USP Fresenius Kabi, a subsidiary of Fresenius, announced the launch of Calcitonin Salmon Injection, USP Synthetic, a calcium-regulating medication designed to treat symptomatic Paget’s disease of the bone and hypercalcemia. This injection is…
GeneDx Integrates with Epic to Expand Genome and Exome Sequencing for Faster Diagnosis and Treatment GeneDx (Nasdaq: WGS), a leader in genomic insights for improved health outcomes, announced the launch of its integration with Aura, Epic’s specialty diagnostics suite. This…
Incyte Reports Q4 and Year-End 2024 Results, Provides 2025 Financial Outlook and R&D Milestones Incyte (Nasdaq: INCY) has announced its financial results for the fourth quarter and full year ended December 31, 2024, along with its financial guidance for 2025.…
Synedgen Appoints Dr. Laura Saward as Chief Scientific Officer Synedgen, Inc., a biotechnology company focused on glycobiology to treat gastrointestinal diseases, has appointed Dr. Laura Saward, PhD, as its Chief Scientific Officer. Dr. Saward brings over 25 years of experience…
Cotiviti to Acquire Edifecs in Strategic Deal Cotiviti, a leader in data-driven healthcare solutions, has announced an agreement to acquire Edifecs, a trailblazer in healthcare data interoperability. This strategic acquisition aims to create a combined platform that will strengthen connectivity…
Aurion Biotech Names Donald Munoz as New Chief Financial Officer Aurion Biotech, Inc. (Aurion), a company dedicated to restoring vision for millions through transformative regenerative therapies, announced today the appointment of Donald Munoz as its new Chief Financial Officer (CFO).…
Cancer Center Welcomes RefleXion’s SCINTIX Therapy with First Installation at BHCC RefleXion Medical, a leader in theranostic oncology, has announced that its RefleXion® X1 platform, featuring SCINTIX® biology-guided radiotherapy, will be installed at Beverly Hills Cancer Center (BHCC). This marks…
AdvanCell Partners with Lilly to Develop Targeted Alpha Therapies for Cancer AdvanCell, a clinical-stage radiopharmaceutical company focused on targeted alpha therapies, today revealed an expansion of its strategic collaboration with Eli Lilly and Company. This expanded partnership aims to research…